Nuvation Bio (NUVB) director’s trust buys 25,000 Class A shares

Rhea-AI Filing Summary

Nuvation Bio Inc. director Robert Mashal, through the Robert D. Mashal 2020 Revocable Trust for which he is sole trustee, made an open-market purchase of 25,000 shares of Class A Common Stock at $4.73 per share. After this indirect transaction by the trust, total holdings reported for this trust-related position increased to 225,000 shares of Nuvation Bio Class A Common Stock.

Insider Trade Summary

Net Buyer: 25,000 shares ($118,250)

Net Buy 1 txn

Insider Mashal Robert

Role null

Bought 25,000 shs ($118K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	25,000	$4.73	$118K

Holdings After Transaction: Class A Common Stock — 225,000 shares (Indirect, By Trust)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 25,000 shares Purchase price: $4.73 per share Shares held after transaction: 225,000 shares +1 more

4 metrics

Shares purchased 25,000 shares Open-market purchase of Class A Common Stock

Purchase price $4.73 per share Price paid in open-market transaction

Shares held after transaction 225,000 shares Indirect holdings by the Mashal 2020 Revocable Trust after trade

Net buy shares 25,000 shares Net change in common stock position reported in Form 4

Key Terms

open-market purchase, Class A Common Stock, indirect ownership, Revocable Trust

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

indirect ownership financial

"ownership_type: indirect; nature_of_ownership: By Trust"

Revocable Trust financial

"Robert D. Mashal 2020 Revocable Trust, of which Reporting Person is the sole trustee"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mashal Robert

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/09/2026		P		25,000	A	$4.73	225,000	I	By Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares are owned directly by the Robert D. Mashal 2020 Revocable Trust, of which Reporting Person is the sole trustee.

	/s/ Stephen Dang, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nuvation Bio (NUVB) report for Robert Mashal?

Nuvation Bio reported that a trust associated with director Robert Mashal bought 25,000 shares of Class A Common Stock in an open-market purchase at $4.73 per share, increasing its reported holdings to 225,000 shares after the transaction.

Was the Nuvation Bio (NUVB) insider transaction a buy or a sell?

The reported insider transaction was a buy. A trust associated with director Robert Mashal executed an open-market purchase of 25,000 Nuvation Bio Class A Common Stock shares at $4.73 per share, raising its indirect holdings to 225,000 shares.

How many Nuvation Bio (NUVB) shares does the Mashal trust hold after the transaction?

Following the reported open-market purchase, the Robert D. Mashal 2020 Revocable Trust holds 225,000 shares of Nuvation Bio Class A Common Stock indirectly, as disclosed in the Form 4, with Mashal serving as the sole trustee of the trust.

At what price were the Nuvation Bio (NUVB) shares purchased in the Form 4 filing?

The shares were purchased at $4.73 per share. The trust associated with director Robert Mashal acquired 25,000 Nuvation Bio Class A Common Stock shares in an open-market transaction at this price, as detailed in the Form 4 filing.

Who owns the Nuvation Bio (NUVB) shares reported in this Form 4 filing?

The shares are owned by the Robert D. Mashal 2020 Revocable Trust, which is reported as holding the Nuvation Bio Class A Common Stock. Director Robert Mashal is disclosed as the sole trustee of this revocable trust in the filing footnote.